Morgan Stanley analyst David Risinger reiterated his Overweight rating and $42 price target on Valeant Pharmaceuticals (NYSE: VRX) after visiting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE